Fig. 3

Methylation-mediated silencing of PCDH17 expression in AML. a Principal component analysis (PCA) of PCDH17 methylation levels determined by targeted bisulfite sequencing. Methylation data of the measured 20 CpG sites across 132 samples (107 AML and 25 normal BM- derived MNCs) is provided in Additional file 4. b Box plot showing average PCDH17 methylation differences in normal controls and AML patients, calculated using the Wilcoxon rank-sum test. c Scatterplot showing the correlation between PCDH17 methylation and PCDH17 expression in AML patients. Spearman’s correlation coefficient (ρ) and P value are indicated. d, e PCDH17 expression (d) and methylation (e) in HL60 cell line before and after 5-aza-dC treatment. The data are shown as mean ± S.D. of triplicate analyses. Statistical significances were determined using Student’s t-tests